Axogen AXGN
Axogen FY 2024: revenue $187.3M, up 18%; diluted EPS −$0.23
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0000805928-25-000017
- Document
- 10-K
Key figures from this report
These are the numbers Axogen reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$187.3M+18% from $159.0M in FY 202310-K income statement, on EDGAR
- Net income−$10.0MAgainst −$21.7M in FY 202310-K income statement, on EDGAR
- Diluted EPS−$0.23Against −$0.51 in FY 202310-K income statement, on EDGAR
- Cash and cash equivalents$27.6M−11% from $31.0M in FY 2023Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations$4.5MAgainst −$5.7M in FY 202310-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 3845 and related industry codes: the same peer list as the financial tables.
- Angiodynamics ANGO public float $436M, Nov 30, 2025
- Orthofix Medical OFIX public float $440M, Jun 30, 2025
- Delcath Systems DCTH public float $420M, Jun 30, 2025
- Ceribell CBLL public float $417M, Jun 30, 2025
- Pulse Biosciences PLSE public float $394M, Jun 30, 2025
